First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed
- Written by PR Newswire
- After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has entered multi-regional Phase II clinical trials in the U.S and China.
- The first human patients were dosed with the drug.
- This is a potentially first-in-class anti-fibrotic drug candidate that has reached clinical...
